12
Aug
2010
Trevena, Inc.: Series B $35M
Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Cardiology, X - G-Protein, X - Pain, XX - PA
Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.
28
Jun
2010
21
May
2010
NeuroTherapeutics Pharma, Inc.: Series B $43M
Posted in I - Series B, Q - 2Q10, R - MID WEST, X - CNS, X - Epilepsy, X - Pain, XX - IL
NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.
12
May
2010
Astute Medical, Inc.: Series B $26.5M
Posted in I - Series B, Q - 2Q10, R - WEST, X - Device (Diagnostic), X - Pain, X - Sepsis, XX - CA
Astute Medical (San Diego, CA) a development-stage diagnostic company focused on the identification and validation of protein biomarkers that can test for hospital acquired acute conditions like sepsis, kidney injury and abdominal pain, closed a $26.5M Series B financing. Participants include Domain Associates, Delphi Ventures, Johnson & Johnson Development Corp. and De Novo Ventures.
14
Apr
2010
Tragara Pharmaceuticals, Inc.: Series B $5M
Posted in I - Series B, Q - 1Q10, R - WEST, X - Inflammation, X - Oncology, X - Pain, XX - CA
Tragara Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on selective biomarker for oncology, pain and inflammation therapeutics, closed a $5M Series B financing. Participants include Domain Associates, Mitsubishi Corp., Morgethaler Ventures, Oxford Bioscience Partners and ProQuest Investments.
05
Apr
2010
11
Mar
2010
Nautilus Neurosciences, Inc.: Series A $14.5M
Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Migraine, X - Neurology, X - Pain, XX - NJ
Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!
04
Feb
2010
Afferent Pharmaceuticals, Inc.: Series A $23M
Posted in I - Series A, Q - 4Q09, R - WEST, X - Pain, XX - CA
Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
31
Jan
2010
SantoSolve, AS: Series C $5.5M
Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Analgesic, X - Pain
SantoSolve (Norway) a clinical-stage biopharmaceutical company focused on topical analgesic products based on non-radioactive strontium for various pain conditions, closed a $5.5M Series C financing. Participants include Teknoinvest, InnovationsKapital and Investinor.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
30
Oct
2009
Zogenix, Inc.: Series B $36M
Posted in I - Series B, Q - 3Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, X - Pain, XX - CA
Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutic, closed a $51M Series B financing. Participants include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Oxford Finance and Abingworth Management.
OnBioVC PARTNERS
-
Where is OnBioVC Content Consumed?
